通过激活JAK2/STAT3信号通路,KIF2C促进了清细胞细胞癌的进展
Hao Deng1, Xiaobo Gong1, Guanghai Ji1
1Department of Urology, The First People's Hospital of Jingzhou, Jingzhou, 434000, PR China.
Molecular and cellular probes
|October 20, 2023
概括
素家族成员2C (KIF2C) 在清细胞细胞癌 (ccRCC) 中被上调,并通过激活JAK2/STAT3通路来促进瘤的进展. 针对KIF2C可能为ccRCC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 清细胞细胞癌 (ccRCC) 是一种具有攻击性的恶性瘤,晚期的治疗选择有限.
- 在ccRCC进展中Kinesin家族成员2C (KIF2C) 的作用仍然不完全理解.
- 研究KIF2C的功能对于开发ccRCC的新型治疗策略至关重要.
研究的目的:
- 阐明素家族成员2C (KIF2C) 在清细胞细胞癌 (ccRCC) 进展中的作用.
- 探索KIF2C在ccRCC中的功能背后的潜在分子机制.
- 评估KIF2C作为ccRCC的潜在治疗点.
主要方法:
- 在ccRCC组织中对KIF2C表达的比较分析与正常组织.
- 对KIF2C表达与临床参数 (等级,阶段,转移) 和患者存活率的相关性分析.
- 功能性测定 (扩散,迁移,入侵) 使用具有KIF2C淘汰或过度表达的ccRCC细胞系.
- 基因组丰富分析 (GSEA) 和西布洛特研究信号通路,特别是JAK2/STAT3.3.
主要成果:
- 在ccRCC组织中,KIF2C表达显著上调,与晚期瘤等级,阶段,转移和较差的患者预后相关.
- KIF2C敲击抑制了ccRCC细胞的增殖,迁移和入侵,而过度表达则增强了这些过程.
- KIF2C激活了JAK2/STAT3信号通路,正如GSEA,相关性分析和西方 blot.所证明的那样.
- 抑制JAK2/STAT3信号传递部分抵消了KIF2C的促进瘤的作用.
结论:
- KIF2C是ccRCC进展的关键驱动因素,与不良临床结果相关.
- KIF2C通过激活JAK2/STAT3信号通路来促进ccRCC.
- KIF2C代表了清晰细胞细胞癌的有前途的新型治疗标.
相关概念视频
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K


